Targeting replication stress in cancer therapy
AABA da Costa, D Chowdhury, GI Shapiro… - Nature reviews Drug …, 2023 - nature.com
Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
Clinical and translational advances in ovarian cancer therapy
PA Konstantinopoulos, UA Matulonis - Nature Cancer, 2023 - nature.com
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
PARP inhibitors: enhancing efficacy through rational combinations
D Bhamidipati, JI Haro-Silerio, TA Yap… - British journal of cancer, 2023 - nature.com
Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …
[HTML][HTML] Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo …
JS Frenel, JW Kim, N Aryal, R Asher, D Berton, L Vidal… - Annals of …, 2022 - Elsevier
Background In the SOLO2 trial (ENGOT Ov-21; NCT01874353), maintenance olaparib in
patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation …
patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation …
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer
N Gupta, TT Huang, S Horibata, JM Lee - Pharmacological research, 2022 - Elsevier
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative …
L Luo, K Keyomarsi - Expert opinion on investigational drugs, 2022 - Taylor & Francis
Introduction Poly (ADP-ribose) polymerase inhibitors (PARPis) are an exciting class of
agents that have shown efficacy, particularly for BRCA-mutant triple-negative breast cancer …
agents that have shown efficacy, particularly for BRCA-mutant triple-negative breast cancer …
PARP inhibitors resistance: mechanisms and perspectives
E Giudice, M Gentile, V Salutari, C Ricci, L Musacchio… - Cancers, 2022 - mdpi.com
Simple Summary This review aims to analyze the emerging issue regarding PARP inhibitor's
resistance in tumors and their consequence on disease prognosis and treatment. Besides …
resistance in tumors and their consequence on disease prognosis and treatment. Besides …
Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance
Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination
repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate …
repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate …
[HTML][HTML] Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review
T Schutte, A Embaby, N Steeghs… - Cancer treatment …, 2023 - Elsevier
Introduction The anti-tumor activity of WEE1 inhibitors (WEE1i) in gynecological
malignancies has recently been demonstrated in clinical trials and its rationale is based on …
malignancies has recently been demonstrated in clinical trials and its rationale is based on …
A new wave of innovations within the DNA damage response
Q Li, W Qian, Y Zhang, L Hu, S Chen… - Signal Transduction and …, 2023 - nature.com
Genome instability has been identified as one of the enabling hallmarks in cancer. DNA
damage response (DDR) network is responsible for maintenance of genome integrity in …
damage response (DDR) network is responsible for maintenance of genome integrity in …